1.Correlation between Female Sex Hormones and Electrodiagnostic Parameters and Clinical Function in Post-menopausal Women with Idiopathic Carpal Tunnel Syndrome.
Azam MOHAMMADI ; Mahshid NASERI ; Hamid NAMAZI ; Mohammad Javad ASHRAF ; Alireza ASHRAF
Journal of Menopausal Medicine 2016;22(2):80-86
OBJECTIVES: To investigate the role of sex-hormonal changes in idiopathic carpal tunnel syndrome (CTS) among post-menopausal women through measuring estrogen receptor (ER) expression in their transverse carpal ligament (TCL) and serum estrogen level, as well as determine the correlation between these factors and electrodiagnostic parameters and Boston score. METHODS: Biopsy samples of TCL were collected from 12 postmenopausal women who had undergone surgery for severe idiopathic CTS; control specimens were collected from 10 postmenopausal women without CTS who had undergone surgery for the other hand pathologies. To determine the distributions of ER in TCL, histological and immunohistochemical examinations were performed. Serum estrogen level was also measured. Electrodiagnosis and Boston questionnaire were used for CTS severity and determination of the patients' function. RESULTS: ER expression in TCL and serum estrogen level were not significantly different in the case group compared to the control group (P = 0.79 and P = 0.88, respectively). Also, there was no correlation between ER expression or serum estrogen level and electrodiagnostic parameters or Boston score. CONCLUSIONS: Sex hormones cannot still be considered as the etiology of idiopathic CTS in postmenopausal women. The role of other factors such as wrist ratio and narrower outlet in females compared to the males should be considered along with hormonal changes.
Biopsy
;
Carpal Tunnel Syndrome*
;
Electrodiagnosis
;
Estrogens
;
Female*
;
Gonadal Steroid Hormones*
;
Hand
;
Humans
;
Ligaments
;
Male
;
Pathology
;
Wrist
2.Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels.
Yaprak ENGIN-ÜSTÜN ; Emel Kıyak ÇAĞLAYAN ; Ayşe Yeşim GÖÇMEN ; Muhammed Fevzi POLAT
Journal of Menopausal Medicine 2016;22(2):76-79
OBJECTIVES: The objective of this study was to describe the levels of chemerin, irisin and apolipoprotein M (apoM) in women with postmenopausal osteoporosis. METHODS: The study included 88 women with postmenopausal osteoporosis. Based on World Health Organization criteria, women with a T-score of ≤–2.5 were defined as osteoporotic. In this case-control study, postmenopausal women with T-score >–1 were selected as controls (n = 88) and case-matched in a 1:1 ratio based on age (within 2 years) and body mass index (BMI) (within 1.0 kg/m2). ApoM, irisin and chemerin levels were determined by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. RESULTS: There were no significant differences in age, BMI, parity, cholesterol and apoM levels between the two groups. C-reactive protein levels were significantly increased in women with osteoporosis. Serum chemerin levels (240.1 ± 46.1 vs. 261.5 ± 50.8 ng/mL) were significantly lower in the women with osteoporosis, as compared to the controls (P = 0.004). Serum irisin levels were also decreased in women with osteoporosis (0.7 ± 0.2 vs. 0.8 ± 0.2 ng/mL; P = 0.007). CONCLUSION: In the present study, osteoporosis was associated with decreased levels of circulating chemerin and irisin. These findings suggested that adipokines might play a role in the pathogenesis of osteoporosis.
Adipokines
;
Apolipoproteins*
;
Body Mass Index
;
C-Reactive Protein
;
Case-Control Studies
;
Cholesterol
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Osteoporosis
;
Osteoporosis, Postmenopausal*
;
Parity
;
World Health Organization
3.Cell Therapy Products in Menopausal Medicine.
Hye Ji CHOI ; Tae Hee KIM ; Soo Ah KIM ; Jun Mo KIM ; Arum LEE ; Hyeon Jin SONG ; Yoo Jin PARK
Journal of Menopausal Medicine 2016;22(2):71-75
The incidence of postmenopausal diseases increases with the age of women. In this review, we introduce cell therapy products, a new treatment for postmenopausal osteoporosis, which often occurs in postmenopausal women. We also figure out the trends of research on cell therapy products and emphasize the necessity and importance of this research for researchers and postmenopausal women. Finally, we suggest the direction for improvement of postmenopausal osteoporosis and research on cell therapy products. We investigated which medication have been used so far. We also examined the development and technical problems of technologies that are currently in use.
Cell- and Tissue-Based Therapy*
;
Female
;
Humans
;
Incidence
;
Menopause
;
Osteoporosis, Postmenopausal
;
Stem Cells
4.Cervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?.
Journal of Menopausal Medicine 2016;22(2):65-70
Cervical cancer is the third most prevalent cancer in women around the world. Recently in Korea, the incidence of cervical cancer has decreased, but in all stages of cervical intraepithelial neoplasia (CIN), CIN has shown a 91% increase from 1999 to 2008. Persistent human papillomavirus (HPV) infection has been found to be the main cause of cervical cancer. HPV types 16 and 18 have been found in 70% of cervical cancer patients around the world. Cervical cancer screening such as cytology has limitations in terms of sensitivity and specificity. A discussion about the need for the HPV test is becoming active in order to compensate for the limitation of cytology. After the role of HPV in cervical cancer was identified, the importance of HPV detection test as a screening was emphasized. Several tests have been developed and each test has its own advantages and disadvantages, and new test method to overcome the disadvantages is still being developed. Today's guidelines and tests are those you would choose from among the large number of cervical cancer screening guidelines and tests, based on the consideration that the selected guidelines and the test are effective.
Cervical Intraepithelial Neoplasia
;
Early Detection of Cancer
;
Female
;
Humans*
;
Incidence
;
Korea
;
Mass Screening*
;
Methods
;
Papillomaviridae
;
Perimenopause*
;
Sensitivity and Specificity
;
Uterine Cervical Neoplasms*
5.Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action.
Fatemeh ABDI ; Hamid MOBEDI ; Nasibeh ROOZBEH
Journal of Menopausal Medicine 2016;22(2):62-64
Menopause is a critical stage of women's life associated with various complaints and distresses. Vasomotor symptoms (VMS), such as hot flushes, night sweats, sleep disturbances, and fatigue, are the most common menopause symptoms affecting about 50% to 80% of middle-aged women. Obviously, these symptoms, resulting from estrogen deficiency during menopause, can exert negative effects on women's health and quality of life and thus require to be managed through approaches such as hormone replacement therapy (HRT). Many herbal treatments for menopause symptoms contain and its components such as 8-prenylnaringenin, 6-PN, isoxanthohumol and xanthohumol. Recent in-vivo studies have highlighted the ability of 8-prenylnaringenin to reduce serum-luteinizing hormone (LH) and follicle-stimulating hormone (FSH), to increase serum prolactin levels and uterine weight, and to induce vaginal hyperplastic epithelium. Previous research has shown that hops extract can strongly bind to both estrogen receptors, stimulate alkaline phosphatase activity in Ishikawa cells, and upregulate presenelin-2 and progesterone receptor mRNA in Ishikawa cells. Numerous clinical trials have documented significant reductions in the frequency of hot flushes following the administration of hop-containing preparations. Nevertheless, further clinical trials with larger sample size and longer follow-up are warranted to confirm such benefits.
Alkaline Phosphatase
;
Epithelium
;
Estrogens
;
Fatigue
;
Female
;
Follicle Stimulating Hormone
;
Follow-Up Studies
;
Hormone Replacement Therapy
;
Hot Flashes
;
Humans
;
Humulus*
;
Menopause
;
Prolactin
;
Quality of Life
;
Receptors, Estrogen
;
Receptors, Progesterone
;
RNA, Messenger
;
Sample Size
;
Sweat
;
Women's Health
6.HIFU: Effects and Clinical Effectiveness of Non-surgical Therapy for Uterine Fibroids.
Ikjin CHANG ; Kyung Jin HWANG ; Ho Jin CHOI ; Hyo Jin YOON ; Eung Seok LEE ; Sun Young CHOI
Journal of Menopausal Medicine 2016;22(2):59-61
No abstract available.
Leiomyoma*
;
Treatment Outcome*
7.Management of Menopausal Symptoms in Mongolia.
Temuulee ENKHBOLD ; Zoljargal JADAMBAA ; Tae Hee KIM
Journal of Menopausal Medicine 2016;22(2):55-58
No abstract available.
Mongolia*
8.Sclerosing Sromal Tumor of the Ovary in Postmenopausal Women: A Report of Two Cases.
Chae Min LEE ; Soyi LIM ; Hyun Yi CHO ; Ji Sung LEE ; Jin Woo SHIN
Journal of Menopausal Medicine 2015;21(2):115-119
Sclerosing stromal tumor (SST) was first delineated as a distinct ovarian sex cord stromal tumor in 1973 by Chalvardjian and Scully. It is a benign neoplasm, distinguished from other ovarian stromal tumors by the production of collagen and a pseudolobular pattern, and it tends to occur in the second and third decades of life in diagnosed patients. We discovered two rare cases of SST in post-menopausal women which are the topic of this report. These case studies are accompanied by a brief review of the literature.
Collagen
;
Female
;
Humans
;
Menopause
;
Ovarian Neoplasms
;
Ovary*
;
Sex Cord-Gonadal Stromal Tumors
9.Autosomal Translocation Patient Who Experienced Premature Menopause: A Case Report.
Tae Hee KIM ; Yesol KIM ; Do Won JEONG ; Eun Gyeong LEE ; Dong Su JEON ; Jun Mo KIM
Journal of Menopausal Medicine 2015;21(2):112-114
Premature ovarian failure (POF) is a condition in which the ovarian functions of hormone production and oocyte development become impaired before the typical age for menopause. POF and early menopause are present in a broad spectrum of gonad dysgenesis, from a complete cessation of ovarian function to an intermittent follicle maturation failure. Actually POF has been identified as a genetic entity (especially chromosome X), but data on genetic factors of premature menopause are limited. Until now, several cases revealed that inactivation of X chromosomes has an effect on ages of premature menopause and females with balanced or unbalanced X-autosome translocations can have several reproductive problems. On the other hand, there have been a few data that was caused by autosome-autosome translocation can lead. Therefore we report a relevant case of POF with translocation between chromosomes 1 and 4. She had her first menstrual period at the age of 12, and after 7 years she stopped menstruation. Chromosomal analysis showed 46, XX, t (1;4) (p22.3;q31.3). While evaluating this rare case, we could review various causes (especially genetic factors) of POF. To remind clinicians about this disease, we report a case of POF caused by autosome-autosome translocation with a literature review.
Female
;
Gonads
;
Hand
;
Humans
;
Menopause
;
Menopause, Premature*
;
Menstruation
;
Oocytes
;
Primary Ovarian Insufficiency
;
X Chromosome
10.Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women.
Jee Yeon LEE ; Hye Sun HYUN ; Hyang Gi PARK ; Ji Hyun SEO ; Eun Young LEE ; Ji Soo LEE ; Dong Yun LEE ; Doo Seok CHOI ; Byung Koo YOON
Journal of Menopausal Medicine 2015;21(2):104-111
OBJECTIVES: This study was conducted to examine the effects of hormone therapy on serum lipid levels in postmenopausal Korean women. METHODS: This retrospective cohort study included 154 healthy postmenopausal Korean women. Seventy-nine women took oral estrogen (conjugated equine estrogen 0.625 mg/day or equivalent), and 75 applied estrogen transdermally using 0.1% 17beta-estradiol gel. Micronized progesterone (MP) was added to 40 women of oral group and 49 women in transdermal group. Serum levels of triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein (a) were measured before, 3 and 6 month after hormone therapy. RESULTS: At baseline, mean body mass index (BMI) were lower (22.76 vs. 23.74 kg/m2) and proportion of family history of cardiovascular disease (CVD) (61 vs. 39%) were higher in oral group. In oral group, LDL-C and lipoprotein(a) levels decreased, and triglyceride and HDL-C levels increased significantly after 3 and 6 months. There was no significant change in lipoprotein levels compared to the baseline in transdermal group. There were also no differences with additional MP. Changing pattern of HDL-C during 6 months was significantly different by the route of estrogen administration. CONCLUSION: Oral estrogen therapy might be more beneficial than transdermal estrogen in terms of lipid in postmenopausal Korean women. The estrogen effects are not influenced by adding MP.
Body Mass Index
;
Cardiovascular Diseases
;
Cholesterol
;
Cohort Studies
;
Drug Administration Routes
;
Estrogens
;
Female
;
Hormone Replacement Therapy
;
Humans
;
Lipoprotein(a)
;
Lipoproteins
;
Progesterone
;
Retrospective Studies
;
Triglycerides